LGND Feb 2025 150.000 call
| Previous close | 1.4000 |
| Open | 1.4000 |
| Bid | 0.1000 |
| Ask | 4.9000 |
| Strike | 150.00 |
| Expiry date | 2025-02-21 |
| Day's range | 1.4000 - 1.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
Simply Wall St.Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?
Ligand Pharmaceuticals (NASDAQ:LGND) has had a great run on the share market with its stock up by a significant 28...
Business WireLigand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
JUPITER, Fla., September 06, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of FILSPARI.
GuruFocus.comInsider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...
The transaction was executed at a price of $105.34 per share, as detailed in the SEC Filing. Following this sale, the insider now owns 49,510 shares of Ligand Pharmaceuticals Inc. Ligand Pharmaceuticals Inc is engaged in the development and licensing of biopharmaceutical assets.
